| Lymphoma, Follicular
Lunsumio vs Rituxan Hycela
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Lunsumio vs Rituxan Hycela with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRituxan Hycela has a higher rate of injection site reactions vs Lunsumio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rituxan Hycela but not Lunsumio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lunsumio
Rituxan Hycela
At A Glance
IV infusion
Every 3 weeks
Bispecific CD20xCD3 T-cell engager
SC injection
Every 3-4 weeks
CD20-directed antibody
Indications
- Lymphoma, Follicular
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
Dosing
Lymphoma, Follicular Step-up dosing: 1 mg IV (Cycle 1 Day 1), 2 mg (Cycle 1 Day 8), 60 mg (Cycle 1 Day 15), 60 mg (Cycle 2 Day 1), then 30 mg every 3 weeks (Cycles 3+); 21-day cycles; administer as IV infusion over a minimum of 4 hours for initial doses.
Lymphoma, Follicular 1,400 mg/23,400 Units SC; for relapsed/refractory FL, once weekly for 3 or 7 weeks following an initial IV rituximab dose (4 or 8 weeks total); for previously untreated FL, on Day 1 of Cycles 2-8 of chemotherapy every 21 days, then maintenance every 8 weeks for 12 doses; for non-progressing FL after CVP, once weekly for 3 weeks every 6 months to a maximum of 16 doses.
Diffuse Large B-Cell Lymphoma 1,400 mg/23,400 Units SC on Day 1 of Cycles 2-8 of CHOP chemotherapy every 21 days for up to 7 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (up to 6-8 cycles total).
Chronic Lymphocytic Leukemia 1,600 mg/26,800 Units SC on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide every 28 days for 5 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (6 cycles total).
Contraindications
—
—
Adverse Reactions
Most common (>=10%) CRS, fatigue, rash, pyrexia, headache, musculoskeletal pain, cough, pruritus, peripheral neuropathy, edema, diarrhea, nausea, dry skin, upper respiratory tract infection, chills, dizziness, insomnia, abdominal pain, arthralgia, dyspnea, skin exfoliation, urinary tract infection
Serious CRS, infections (sepsis, pneumonia, urinary tract infection, EBV viremia, COVID-19, upper respiratory tract infection), renal insufficiency, pyrexia, tumor flare
Most common (>=20%) Infections, neutropenia, nausea, constipation, cough, fatigue (FL); infections, neutropenia, alopecia, nausea, anemia (DLBCL); infections, neutropenia, nausea, thrombocytopenia, pyrexia, vomiting, injection site erythema (CLL).
Serious Mucocutaneous reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy, hypersensitivity and administration reactions, tumor lysis syndrome, infections, cardiac arrhythmias, renal toxicity, bowel obstruction and perforation.
Postmarketing Prolonged pancytopenia, fatal cardiac failure, uveitis, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease.
Pharmacology
Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engaging antibody that binds CD3 on T-cells and CD20 on lymphoma and B-lineage cells, activating T-cells to induce B-cell lysis and cytokine release.
Anti-CD20 chimeric murine/human IgG1 monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC); combined with hyaluronidase human, which transiently depolymerizes subcutaneous hyaluronan to enhance rituximab absorption into systemic circulation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lunsumio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Rituxan Hycela
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lunsumio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rituxan Hycela
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lunsumio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Rituxan Hycela
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rituxan Hycela.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LunsumioView full Lunsumio profile
Rituxan HycelaView full Rituxan Hycela profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.